Fortunately, recent studies show that anti-HMGB1 monoclonal antibodies (mAb) treatment might be effective in treating a wide range of central nervous system (CNS) and peripheral nervous system (PNS) disorders such as epilepsy [32, 33]. Here, HMGB1 is linked to epilepsy.